Advances in the preclinical and clinical research of proteolysis targeting chimera / 生物工程学报
Chinese Journal of Biotechnology
;
(12): 3615-3627, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-1007981
ABSTRACT
Proteolysis targeting chimera (PROTAC) refers to heterobifunctional small molecules that can simultaneously bind an E3 ubiquitin ligase and a target protein, enabling specific degradation of the target protein with the aid of the ubiquitin proteasome system. At present, most PROTAC drugs are in the clinical trial stage, and the ligands are mainly non-covalent compounds. PROTAC drugs have the advantage of overcoming drug resistance and degrading "undruggable" target proteins, but non-covalent ligands could lead to the hook effect that undermines drug efficacy. With its own advantages, covalent ligands can avoid the occurrence of this phenomenon, which is of great help to the development of PROTAC. This review summarizes the progress in preclinical and clinical research and application of PROTAC molecules targeting three different classes of protein targets, including intranuclear, transmembrane, and cytosolic proteins. We also offer perspective discussions to provide research ideas and references for the future development of PROTAC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Proteins
/
Ubiquitin-Protein Ligases
/
Proteasome Endopeptidase Complex
/
Proteolysis
/
Proteolysis Targeting Chimera
/
Ligands
Language:
Chinese
Journal:
Chinese Journal of Biotechnology
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS